Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98–NSD1 fusion gene

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Bloomfield CD, Shuma C, Regal L, Philip PP, Hossfeld DK, Hagemeijer AM et al. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer 1997; 80: 2191–2198.

    Article  CAS  PubMed  Google Scholar 

  2. Schoch C, Haferlach T, Haase D, Fonatsch C, Loffler H, Schlegelberger B et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001; 112: 118–126.

    Article  CAS  PubMed  Google Scholar 

  3. Krauter J, Peter W, Pascheberg U, Heinze B, Bergmann L, Hoelzer D et al. Detection of karyotypic aberrations in acute myeloblastic leukaemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML. Br J Haematol 1998; 103: 72–78.

    Article  CAS  PubMed  Google Scholar 

  4. Slape C, Aplan PD . The role of NUP98 gene fusions in hematologic malignancy. Leuk Lymphoma 2004; 45: 1341–1350.

    Article  CAS  PubMed  Google Scholar 

  5. Huang N, vom BE, Garnier JM, Lerouge T, Vonesch JL, Lutz Y et al. Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators. EMBO J 1998; 17: 3398–3412.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kurotaki N, Harada N, Yoshiura K, Sugano S, Niikawa N, Matsumoto N . Molecular characterization of NSD1, a human homologue of the mouse Nsd1 gene. Gene 2001; 279: 197–204.

    Article  CAS  PubMed  Google Scholar 

  7. Wang GG, Cai L, Pasillas MP, Kamps MP . NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 2007; 9: 804–812.

    Article  CAS  PubMed  Google Scholar 

  8. Hollink IH, Van den Heuvel-Eibrink MM, rentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 2011; 118: 3645–3656.

    Article  CAS  PubMed  Google Scholar 

  9. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825–1832.

    Article  CAS  PubMed  Google Scholar 

  10. Chou WC, Chen CY, Hou HA, Lin LI, Tang JL, Yao M et al. Acute myeloid leukemia bearing t(7;11)(p15;p15) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile: comparative analysis of 493 adult patients. Leukemia 2009; 23: 1303–1310.

    Article  CAS  PubMed  Google Scholar 

  11. Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies. Leukemia 2006; 20: 1295–1297.

    Article  CAS  PubMed  Google Scholar 

  12. Taketani T, Taki T, Nakamura T, Kobayashi Y, Ito E, Fukuda S et al. High frequencies of simultaneous FLT3-ITD, WT1 and KIT mutations in hematological malignancies with NUP98-fusion genes. Leukemia 2010; 24: 1975–1977.

    Article  CAS  PubMed  Google Scholar 

  13. Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA . The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 2001; 20: 1897–1909.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. King-Underwood L, Pritchard-Jones K . Wilms’ tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998; 91: 2961–2968.

    CAS  PubMed  Google Scholar 

  15. Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002; 100: 4372–4380.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all clinicians for sending samples to our laboratory for diagnostic purposes, and for providing clinical information and follow-up data. In addition, we would like to thank all the co-workers at the MLL (Munich Leukemia Laboratory) for approaching together many aspects in the field of leukemia diagnostics and research. Especially the technical assistance of Nicole Schlenther, who performed NUP98–NSD1-specific qRT-PCR analyses, is greatly appreciated. In addition, we are grateful for the data management support performed by Tamara Alpermann.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S Schnittger.

Ethics declarations

Competing interests

CH, WK, TH, and SS have equity ownership of MLL Munich Leukemia Laboratory GmbH. AF and TA are employed by MLL Munich Leukemia Laboratory GmbH.

Additional information

Supplementary information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fasan, A., Haferlach, C., Alpermann, T. et al. A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98–NSD1 fusion gene. Leukemia 27, 245–248 (2013). https://doi.org/10.1038/leu.2012.230

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2012.230

This article is cited by

Search

Quick links